Skip to main content

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment.

After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23.

The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector.

In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down.

The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore.

Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal.

Light at the end of the tunnel

Titan can get benefits from the strong market share in the jewellery and wrist watches segment mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment.

Brokerages highlight Titan has major revenue and EBIDTA comes from the jewellery segment which is highly sensitive to the overall macro-economic scenario. The company also benefits out of a large share of franchisee sales which helps more in the current times of underutilization.

Reports indicate Tanishq revenues have recovered to 90 percent of pre-COVID levels – significantly ahead of consensus expectations.

Brokerage firm ICICI Securities has upgraded the stock to 'add' from 'hold', with a DCF-based revised target price of Rs 1,250 from Rs 1,100 earlier.

The brokerage has increased FY22 earnings estimates by nearly 2 percent and modelled revenue, EBITDA and PAT CAGR of 14, 13 and 16 percent, respectively over FY20-22E.


"A


s Tanishq revenues have recovered significantly ahead of consensus expectations, likely drivers of this trend are (1) boost to volumes due to (somewhat) stable gold prices, (2) consumers have (likely) started accepting higher gold prices and expect further inflation and (3) market share gains (liquidity challenges for smaller competitors)," ICICI Securities said.

"Upside trigger is gold price correction or volatility leading to a surge in volumes. That said, the introduction of fixed making charges, even though a small proportion currently, is something that we will watch carefully," the brokerage added.

Brokerage firm HDFC Securities has a buy call on the stock with a base case fair value of Rs 1,192 and a bull case fair value of Rs 1,266 for six months.

HDFC Securities is of the view that the Indian retail industry is likely to go through a strong consolidation phase which is likely to benefit companies of the likes of Titan mainly due to its robust balance sheet and

phenomenal track record of consistent market share gains.

The brokerage added that the management continued focus on new launches and consistent expansion of the product portfolio by entering into newer categories is further likely to fuel future growth.

The brokerage expects that COVID-19 led lockdown and slowdown in the economy will lead to subdued growth and sluggish operational performance in FY21.

"Titan is a structural growth story and is a strong play on the consumption theme and rides on the long-term opportunity on rising income, increased discretionary spending, gains from penetration and premiumisation trends," HDFC Securities said.

Disclaimer: The views and investment tips expressed by investment experts on SD Solutions are their own and not that of the website or its management. SD Solutions advises users to check with certified experts before taking any investment decisions.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more